Unknown

Dataset Information

0

Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.


ABSTRACT:

Background

The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon ? (PegIFN)-? plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination.

Objective

To analyse the safety and efficacy of Peg-IFN?/ribavirin/protease inhibitor combination in HCV-MC vasculitis.

Patients and methods

Open-label, prospective, cohort study including 23 patients with HCV-MC vasculitis. Peg-IFN?/ribavirin was associated to telaprevir (375 mg three times daily, for 12 weeks, (n=15)) or boceprevir (800 mg three times daily, for 44 weeks, (n=8)) for 48 weeks.

Results

The median age was 59 (52.5-66) years, with 48.8% women. Thirteen patients (56.5%) were complete clinical responders, and 10 (43.5%) were partial responders at week 24. The virological response (ie, HCV RNA negativation) was of 69.6% at week 24 (p=0.005). The cryoglobulin level decreased from 0.44 to 0.06 g/l (p=0.0006) and the C4 level increased from 0.09 to 0.15 g/l (p=0.045). Grades 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 10 cases (43.5%). Twenty patients (87%) received erythropoietin, 9 (39.1%) had red cell transfusion, and 2 (8.7%) had granulocyte stimulating agents. Antiviral therapy discontinuation was required in 8 (34.7%) patients for virological non-response (n=5), virological relapse (n=2) and depression (n=1).

Conclusions

Peg-IFN?/ribavirin/protease inhibitor combination seems highly effective in HCV-MC. Such therapeutic regimen should be administered cautiously considering the high rate of side effects.

SUBMITTER: Saadoun D 

PROVIDER: S-EPMC3995244 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.

Saadoun David D   Resche Rigon M M   Thibault V V   Longuet M M   Pol S S   Blanc F F   Pialoux G G   Karras A A   Bazin-Karra D D   Cazorla C C   Vittecoq D D   Musset L L   Decaux O O   Ziza J M JM   Lambotte O O   Cacoub Patrice P  

Annals of the rheumatic diseases 20130420 5


<h4>Background</h4>The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination.<h4>Objective</h4>To analyse the safety and efficacy of Peg-IFNα/ribavirin/protease inhibitor combination in HCV-MC vasculitis.<h4>Patients and methods</h4>Open-label, prospective, cohort study including 23 patients w  ...[more]

Similar Datasets

| S-EPMC4985415 | biostudies-literature
| S-EPMC3877658 | biostudies-literature
2010-01-04 | PRD000181 | Pride
| S-EPMC4344648 | biostudies-literature
| S-EPMC4330713 | biostudies-literature
| S-EPMC3895210 | biostudies-literature
| S-EPMC3994015 | biostudies-literature
| S-EPMC3644280 | biostudies-literature
| S-EPMC7202429 | biostudies-literature
| S-EPMC8216391 | biostudies-literature